• Target Injection Depth: Injection depth is restricted to the supraperiosteal or deep subcutaneous plane, where the 23G needle supports deep structural product placement.
• Pain Management: Co-formulated lidocaine (3 mg/mL) provides localized analgesia for deep-plane treatments involving larger zones and greater tissue manipulation; supplemental block anesthesia remains optional for longer sessions.
• Infection Control: Strict aseptic technique must be maintained throughout to prevent contamination.
• Vascular Safety: Intravascular injection must be avoided entirely and requires advanced deep-plane injection competence.
• Sun Exposure Advice: Post-treatment guidance should instruct patients to avoid sun exposure until all redness and swelling resolve.
• Swelling Expectations: Patients should be advised that deep-plane swelling may be more pronounced and longer-lasting than with more superficial formulations.
• Adverse Events & Warnings: Key critical risks and warnings include vascular occlusion, skin necrosis, visual disturbance, and transient bruising at the injection site.

• Can treat severe volume loss involving significant facial volume deficit in the cheeks, temples, midface, and jawline.
• Indicated for deep facial volumization and structural contouring of the cheekbones, chin, and jawline at the supraperiosteal or deep subcutaneous plane.
• Designed for nasolabial folds and marionette lines with a major volume component, as a deep correction layer.
• Prescribed for licensed aesthetic medicine professionals with deep-plane injection experience; not for self-administration.

Product Specifications

• Active ingredient: Cross-linked hyaluronic acid 26 mg/g; lidocaine 3 mg/mL.
• Format: Injectable gel supplied in 2 × 1 mL prefilled syringes (BI-FLEX® syringe system) with 2 × 23G 1¼” needles and 2 × 27G ½” needles
• Manufacturer: Laboratoires VIVACY, France.
• Drug class: Injectable cross-linked hyaluronic acid dermal filler; highest concentration in the STYLAGE® range; deep-plane formulation with lidocaine.
• Regulatory status: CE-marked for EU use; US FDA status should be verified by jurisdiction before procurement.

Contraindications

• Do not administer to patients with known hypersensitivity to hyaluronic acid, lidocaine, amide-type anesthetics, or any excipient in the formulation.
• Do not inject into areas with active skin infection or inflammation at the intended treatment site.
• Avoid use during pregnancy or breastfeeding as a precaution, due to limited safety data in these populations.

• For supraperiosteal or deep subcutaneous injection only; reserve for cases where lighter STYLAGE® formulations such as M or L cannot achieve the required structural correction.
• Supplemental block anesthesia is optional, as lidocaine is co-formulated at 3 mg/mL.
• Allow the syringe to reach room temperature before administration.
• The product is intended for single use only; discard any unused gel, syringe, and needle after the procedure.
• Screen for hypersensitivity to hyaluronic acid and amide-type anesthetics before treatment and refer to the full IFU.

STYLAGE® XL BI-FLEX® with Lidocaine is a CE-marked medical device manufactured by Laboratoires VIVACY (France). Its regulatory status in other jurisdictions, including the United States, should be verified before procurement. Practitioners who wish to buy dermal fillers or buy STYLAGE® may contact the Med Supply Solutions support team for sourcing information and documentation support.

1. Mojallal A. Efficacy and Safety of Stylage XL Lidocaine for the Restoration and/or Augmentation of Facial Volume: The Beauty Volume Study. Aesthet Surg J Open Forum. 2023;5:ojad056. Published 2023 Jun 26. doi:10.1093/asjof/ojad056
2. Ramos-E-Silva M, Fonteles LA, Lagalhard CS, Fucci-da-Costa AP. STYLAGE®: a range of hyaluronic acid dermal fillers containing mannitol. Physical properties and review of the literature. Clin Cosmet Investig Dermatol. 2013;6:257-261. Published 2013 Oct 23. doi:10.2147/CCID.S35251
3. Pignatti M, Pedone A, Baccarani A, et al. High-density hyaluronic acid for the treatment of HIV-related facial lipoatrophy. Aesthetic Plast Surg. 2012;36(1):180-185. doi:10.1007/s00266-011-9771-3

The contents of this page are meant for licensed medical professionals. They serve informational purposes only and are not to be taken as medical advice.